A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease
This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind, placebo-controlled, lead-in study RVT-101-3001 (double-blind study).
This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind, placebo-controlled, lead-in study RVT-101-3001. Various background therapies, including acetylcholinesterase inhibitors and memantine, will be allowed.
Inclusion Criteria:
Exclusion Criteria:
Ciudad Autonoma de Buenos Aire, C1012AAR, Argentina
Ciudad Autonoma de Buenos Aire, C1058AAJ, Argentina
Ciudad Autonoma de Buenos Aire, C1111AAL, Argentina
Ciudad Autonoma de Buenos Aire, C1117ABH, Argentina
Ciudad Autonoma de Buenos Aire, C1406BOA, Argentina
Ciudad Autonoma de Buenos Aire, C1428AQK, Argentina
Ciudad Autónoma de Buenos Aire, C1405BCK, Argentina
Ciudad Autónoma de Buenos Aire, C1425AHQ, Argentina
North York, Ontario M3B 2S7, Canada